Cost-effectiveness analysis of tucatinib plus trastuzumab versus pertuzumab plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer
Expert Review of Pharmacoeconomics & Outcomes Research · 21.04.2026 · 26 (4) · 537-547
DOI: 10.1080/14737167.2026.2642646 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, online erschienen am 09.03.2026. Verfasst von Mengmeng Liu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Harbin Medical University Cancer Hospital, Harbin, China. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Colorectal Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: the Scientific Research Project of Heilongjiang Provincial Health Commission, Haiyan Foundation of Harbin Medical University Cancer Hospital.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Harbin Medical University Cancer Hospital, Harbin, China.
Förderung
- the Scientific Research Project of Heilongjiang Provincial Health Commission
- Haiyan Foundation of Harbin Medical University Cancer Hospital
Zitieren
APA
Liu, M., Zhong, L., Dong, M., & Liu, T. (2026). Cost-effectiveness analysis of tucatinib plus trastuzumab versus pertuzumab plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer. Expert Review of Pharmacoeconomics & Outcomes Research, 26(4), 537-547. https://doi.org/10.1080/14737167.2026.2642646
Vancouver
Liu M, Zhong L, Dong M, Liu T. Cost-effectiveness analysis of tucatinib plus trastuzumab versus pertuzumab plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer. Expert Review of Pharmacoeconomics & Outcomes Research. 2026;26(4):537-547. doi:10.1080/14737167.2026.2642646
BibTeX
@article{Liu2026,
author = {Liu, Mengmeng and Zhong, Lu and Dong, Mei and Liu, Tong},
title = {Cost-effectiveness analysis of tucatinib plus trastuzumab versus pertuzumab plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer},
journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
year = {2026},
volume = {26},
number = {4},
pages = {537--547},
doi = {10.1080/14737167.2026.2642646}
}
EUVIMED